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THE ACTION OF NUTRACEUTICALS ON KEY MACROPHAGE 
PROCESSES ASSOCIATED WITH ATHEROSCLEROSIS 
 
Objectives: To investigate the actions of nutraceuticals on key macrophage 
processes associated with atherosclerosis. 
 
Background: Atherosclerosis is an inflammatory disorder of the vasculature 
orchestrated by the action of cytokines. Macrophages play a pivotal role in 
atherosclerosis and represent promising therapeutic targets. Current therapies 
against atherosclerosis are associated with substantial residual risk together with 
other issues such as adverse side effects. In addition, there have been numerous 
disappointments on many pharmaceutical agents identified from drug discovery 
programs. This has initiated interest in nutraceuticals as preventative or therapeutic 
agents in atherosclerosis but requires an in-depth understanding of their actions. 
The purpose of this study was to delineate the effects of nutraceuticals on key 
macrophage processes associated with atherosclerosis together with the molecular 
mechanisms underlying their actions. 
 
Methods: The studies used a combination of macrophage cell lines and primary 
cultures. Gene expression was monitored by real time quantitative PCR and 
western blot analysis. The production of reactive oxygen species was determined 
using a kit from Abcam. Foam cell formation was monitored by uptake of 
fluorescently labeled modified LDL, intracellular lipid profile and cholesterol 
efflux. Inflammasome activation was evaluated by following the release of 
interleukin (IL)-1beta. Cell viability was assessed by release of lactate 
dehydrogenase. 
 
Results: The studies focused on key components in olive oil and omega-6 
polyunsaturated fatty acids. These attenuated the expression of key markers of 
inflammation induced by several pro-atherogenic cytokines, the uptake of modified 
LDL, macropinocytosis and foam cell formation in macrophages. In addition, they 
stimulated macrophage cholesterol efflux. A differential effect was observed for 
other parameters such as production of reactive oxygen species and production of 
IL-1beta via inflammasome activation. The mechanisms underlying such actions 
will be presented. 
 
Conclusions: The studies provide novel insights into the actions of nutraceuticals 
on key macrophage processes associated with atherosclerosis. 
 
